Literature DB >> 20559478

Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy.

B Sergi1, G Conti, G Paludetti.   

Abstract

This study aimed to evaluate audiological and vestibular involvement in Fabry disease and the effects of enzyme replacement therapy with human alpha-galactosidase A. The study population comprised 20 patients (11 males, 9 females) aged 15-69 years (mean 39.7). Patients underwent a complete clinical and instrumental evaluation before starting and during enzyme replacement therapy. Median follow-up was 51.5 months (range 25-73). Nine patients (45%) complained of hearing symptoms (hearing loss, tinnitus); for six of them the onset and/or progression of the hearing loss were sudden. Vertigo or dizziness was reported by 6 patients (30%). Audiological evaluation showed a sensorineural hearing loss in 18 ears (45%; 10 in male patients, 8 in females). The hearing thresholds for 0.5, 1, 2 and 4 kHz frequencies ranged from 10 to 65 dB HL. Hearing loss was unilateral in 8 cases (40%; 4 in male patients, 4 in females). Also high frequency hearing loss for 4 and 8 kHz was evaluated. No signs of retro-cochlear lesions were observed by means of otoacoustic emissions and auditory brainstem response. Vestibular examinations showed a functional impairment in 7 ears (17.5%, all male patients). During enzyme replacement therapy the auditory function showed some degrees of worsening but no significant changes were observed at statistical analysis. In conclusion involvement of the inner ear is common in men and women with Fabry disease. In this study, a high incidence of cochlear hearing loss was found, which was typically unilateral and showed onset and/or progression by sudden episodes. Vascular or hydropic mechanisms could be hypothesized to explain audiological findings. Vestibular involvement showed a lower incidence and different pattern, thus suggesting that several patho-physiological mechanisms could play a role in determining inner ear damage in Fabry disease. Results obtained show that enzyme replacement therapy may stabilize hearing function; however, further studies on the physiopathology of the inner ear damage are needed.

Entities:  

Keywords:  Enzyme replacement therapy; Fabry disease; Inner ear; Sensorineural hearing loss; Vestibular damage; α-galactosidase A

Mesh:

Substances:

Year:  2010        PMID: 20559478      PMCID: PMC2882147     

Source DB:  PubMed          Journal:  Acta Otorhinolaryngol Ital        ISSN: 0392-100X            Impact factor:   2.124


  16 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

3.  Hearing loss in a family affected by Fabry disease.

Authors:  Bruno Sergi; Guido Conti
Journal:  J Inherit Metab Dis       Date:  2007-05-09       Impact factor: 4.982

Review 4.  Sudden sensorineural hearing loss.

Authors:  G B Hughes; M A Freedman; T J Haberkamp; M E Guay
Journal:  Otolaryngol Clin North Am       Date:  1996-06       Impact factor: 3.346

5.  Hearing loss in Fabry disease: data from the Fabry Outcome Survey.

Authors:  S Hegemann; D Hajioff; G Conti; M Beck; G Sunder-Plassmann; U Widmer; A Mehta; A Keilmann
Journal:  Eur J Clin Invest       Date:  2006-09       Impact factor: 4.686

6.  Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Authors:  R Schiffmann; G J Murray; D Treco; P Daniel; M Sellos-Moura; M Myers; J M Quirk; G C Zirzow; M Borowski; K Loveday; T Anderson; F Gillespie; K L Oliver; N O Jeffries; E Doo; T J Liang; C Kreps; K Gunter; K Frei; K Crutchfield; R F Selden; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

7.  A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

Authors:  C M Eng; M Banikazemi; R E Gordon; M Goldman; R Phelps; L Kim; A Gass; J Winston; S Dikman; J T Fallon; S Brodie; C B Stacy; D Mehta; R Parsons; K Norton; M O'Callaghan; R J Desnick
Journal:  Am J Hum Genet       Date:  2001-02-01       Impact factor: 11.025

8.  Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.

Authors:  D Hajioff; Y Enever; R Quiney; J Zuckerman; K Mackermot; A Mehta
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

10.  Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.

Authors:  Dominique P Germain; Paul Avan; Augustin Chassaing; Pierre Bonfils
Journal:  BMC Med Genet       Date:  2002-10-11       Impact factor: 2.103

View more
  9 in total

1.  Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.

Authors:  Eefje B Suntjens; Bouwien E Smid; Marieke Biegstraaten; Wouter A Dreschler; Carla E M Hollak; Gabor E Linthorst
Journal:  J Inherit Metab Dis       Date:  2014-11-14       Impact factor: 4.982

2.  Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta.

Authors:  Politei Juan; Amartino Hernan; Schenone Andrea Beatriz; Cabrera Gustavo; Michref Antonio; Tanus Eduardo; Dominguez Raul; Larralde Margarita; Blanco Mariana; Gaggioli Daniela; Szlago Marina
Journal:  JIMD Rep       Date:  2014-05-22

3.  Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?

Authors:  Carla Pinto Moura; Carlos Soares; Daniela Seixas; Margarida Ayres-Bastos; João Paulo Oliveira
Journal:  JIMD Rep       Date:  2012-03-24

Review 4.  Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review.

Authors:  Claudia Regenbogen; Matthias Christoph Braunisch; Christoph Schmaderer; Uwe Heemann
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

5.  Prevalence of Fabry disease in men with tinnitus and sensorineural hearing loss.

Authors:  Richard Holy; Tereza Hlozkova; Klara Prochazkova; David Kalfert; Frantiska Hybnerova; Denisa Ebelova; Berthold Streubel; Martin Chovanec; Bretislav Gal; Ales Linhart; Jaromir Astl
Journal:  J Appl Biomed       Date:  2021-01-28       Impact factor: 1.797

6.  Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease.

Authors:  Maria Köping; Wafaa Shehata-Dieler; Mario Cebulla; Kristen Rak; Daniel Oder; Jonas Müntze; Peter Nordbeck; Christoph Wanner; Rudolf Hagen; Sebastian Schraven
Journal:  PLoS One       Date:  2017-11-21       Impact factor: 3.240

7.  Neuro-Otological and Peripheral Nerve Involvement in Fabry Disease.

Authors:  Sergio Carmona; Romina Weinschelbaum; Ana Pardal; Cintia Marchesoni; Paz Zuberbuhler; Patricia Acosta; Guillermo Cáceres; Isaac Kisinovsky; Luciana Bayón; Ricardo Reisin
Journal:  Audiol Res       Date:  2017-07-28

8.  Characterization of vertigo and hearing loss in patients with Fabry disease.

Authors:  Maria Köping; Wafaa Shehata-Dieler; Dieter Schneider; Mario Cebulla; Daniel Oder; Jonas Müntze; Peter Nordbeck; Christoph Wanner; Rudolf Hagen; Sebastian P Schraven
Journal:  Orphanet J Rare Dis       Date:  2018-08-15       Impact factor: 4.123

Review 9.  The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Authors:  Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada
Journal:  Mol Genet Metab Rep       Date:  2019-02-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.